BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 30817944)

  • 21. Cyproterone acetate enhances TRAIL-induced androgen-independent prostate cancer cell apoptosis via up-regulation of death receptor 5.
    Chen L; Wolff DW; Xie Y; Lin MF; Tu Y
    BMC Cancer; 2017 Mar; 17(1):179. PubMed ID: 28270124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of Akt signaling by the lignan matairesinol sensitizes prostate cancer cells to TRAIL-induced apoptosis.
    Peuhu E; Rivero-Müller A; Stykki H; Torvaldson E; Holmbom T; Eklund P; Unkila M; Sjöholm R; Eriksson JE
    Oncogene; 2010 Feb; 29(6):898-908. PubMed ID: 19935713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. eNOS protects prostate cancer cells from TRAIL-induced apoptosis.
    Tong X; Li H
    Cancer Lett; 2004 Jul; 210(1):63-71. PubMed ID: 15172122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Butein sensitizes human hepatoma cells to TRAIL-induced apoptosis via extracellular signal-regulated kinase/Sp1-dependent DR5 upregulation and NF-kappaB inactivation.
    Moon DO; Kim MO; Choi YH; Kim GY
    Mol Cancer Ther; 2010 Jun; 9(6):1583-95. PubMed ID: 20515942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Camptothecin sensitizes human hepatoma Hep3B cells to TRAIL-mediated apoptosis via ROS-dependent death receptor 5 upregulation with the involvement of MAPKs.
    Jayasooriya RG; Choi YH; Hyun JW; Kim GY
    Environ Toxicol Pharmacol; 2014 Nov; 38(3):959-67. PubMed ID: 25461556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner.
    Chen M; Wang X; Zha D; Cai F; Zhang W; He Y; Huang Q; Zhuang H; Hua ZC
    Sci Rep; 2016 Oct; 6():35468. PubMed ID: 27752089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucocorticoid receptor antagonist sensitizes TRAIL-induced apoptosis in renal carcinoma cells through up-regulation of DR5 and down-regulation of c-FLIP(L) and Bcl-2.
    Min KJ; Jang JH; Lee JT; Choi KS; Kwon TK
    J Mol Med (Berl); 2012 Mar; 90(3):309-19. PubMed ID: 22008998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms.
    Shankar S; Singh TR; Srivastava RK
    Prostate; 2004 Sep; 61(1):35-49. PubMed ID: 15287092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation.
    Kim EH; Yoon MJ; Kim SU; Kwon TK; Sohn S; Choi KS
    Cancer Res; 2008 Jan; 68(1):266-75. PubMed ID: 18172319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade.
    Das S; Tripathi N; Preet R; Siddharth S; Nayak A; Bharatam PV; Kundu CN
    Oncotarget; 2017 Jan; 8(1):248-267. PubMed ID: 27542249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells.
    Shlyakhtina Y; Pavet V; Gronemeyer H
    Cell Death Dis; 2017 Aug; 8(8):e3025. PubMed ID: 29048428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Snake venom toxin from Vipera lebetina turanica sensitizes cancer cells to TRAIL through ROS- and JNK-mediated upregulation of death receptors and downregulation of survival proteins.
    Park MH; Jo M; Won D; Song HS; Song MJ; Hong JT
    Apoptosis; 2012 Dec; 17(12):1316-26. PubMed ID: 23007278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Triptolide sensitizes TRAIL-induced apoptosis in prostate cancer cells via p53-mediated DR5 up-regulation.
    Xiaowen H; Yi S
    Mol Biol Rep; 2012 Sep; 39(9):8763-70. PubMed ID: 22707197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 5, 7-Dimethoxyflavone sensitizes TRAIL-induced apoptosis through DR5 upregulation in hepatocellular carcinoma cells.
    Yang JF; Cao JG; Tian L; Liu F
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):195-206. PubMed ID: 21660448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ursolic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis.
    Shin SW; Park JW
    Biochim Biophys Acta; 2013 Mar; 1833(3):723-30. PubMed ID: 23247106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pretreatment of docetaxel enhances TRAIL-mediated apoptosis in prostate cancer cells.
    Yoo J; Park SS; Lee YJ
    J Cell Biochem; 2008 Aug; 104(5):1636-46. PubMed ID: 18404675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inorganic selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide/p53/Bax-mediated activation of mitochondrial pathway.
    Hu H; Jiang C; Schuster T; Li GX; Daniel PT; Lü J
    Mol Cancer Ther; 2006 Jul; 5(7):1873-82. PubMed ID: 16891474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Notch1 signaling sensitizes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human hepatocellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53 degradation and up-regulating p53-dependent DR5 expression.
    Wang C; Qi R; Li N; Wang Z; An H; Zhang Q; Yu Y; Cao X
    J Biol Chem; 2009 Jun; 284(24):16183-16190. PubMed ID: 19376776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Capsaicin sensitizes malignant glioma cells to TRAIL-mediated apoptosis via DR5 upregulation and survivin downregulation.
    Kim JY; Kim EH; Kim SU; Kwon TK; Choi KS
    Carcinogenesis; 2010 Mar; 31(3):367-75. PubMed ID: 19939880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cisplatin-mediated c-myc overexpression and cytochrome c (cyt c) release result in the up-regulation of the death receptors DR4 and DR5 and the activation of caspase 3 and caspase 9, likely responsible for the TRAIL-sensitizing effect of cisplatin.
    Zhu X; Zhang K; Wang Q; Chen S; Gou Y; Cui Y; Li Q
    Med Oncol; 2015 Apr; 32(4):133. PubMed ID: 25796504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.